NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)

Launched by ASTRAZENECA · Mar 17, 2025

Keywords

ClinConnect Summary

This is a multi-center, prospective, non-interventional study (NIS) to collect real-world clinical and PRO data in patients with primary advanced (FIGO stage III or IV) or recurrent EC receiving 1L CPD followed by maintenance therapy with durvalumab (DNA mismatch repair deficient; dMMR cohort) or durvalumab and olaparib (DNA mismatch repair proficient, pMMR cohort) in accordance with the applicable SmPC within routine clinical practice. Following surgery and/or radiation (if applicable) the decision to initiate 1L CPD followed by durvalumab or durvalumab and olaparib is made in a shared dec...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women aged ≥ 18 years at the time of screening.
• * Patient has pathologically documented:
• • Primary advanced (FIGO III and IV) epithelial EC OR
• • Recurrent disease that is unlikely to be cured and where the multidisciplinary tumor board decision is systemic therapy. Carcinosarcomas are allowed,
• • Patient is intended or initiated to receive 1L CPD followed by maintenance therapy with durvalumab (dMMR cohort) or with durvalumab and olaparib (pMMR cohort) according to the SmPC of IMFINZI® and Lynparza®\* prior to enrollment. Recruitment of patients that already started and may have received up to 2 cycles of CPD is allowed but will be capped to 25% of the study population.
• • Patient is eligible for treatment with durvalumab and/or olaparib as specified in the IMFINZI® and Lynparza® SmPC. The prescription of the medicinal product is clearly separated from the decision to include the patient in the study.
• • MMR-testing results of the patient's tumor are known.
• • Patient is willing and able to complete PRO questionnaires.
• • Patient can read and understand German, English, Arab, Russian or Turkish.
• • Signed written informed consent.
• Exclusion Criteria:
• • Patient has already received ≥2 cycles of 1L CPD
• • Known hypersensitivity to carboplatin, paclitaxel, durvalumab and/or olaparib or any of the excipients of the drug.
• • Pregnancy or breast-feeding.
• • Unable to swallow orally administered medication.
• • Current or planned participation in an interventional clinical trial.
• • Current or planned systemic treatment of any tumor other than primary advanced or recurrent EC.
• • Patient has pathologically documented sarcoma